Description:
Invention Summary
The technology relates to chemotherapeutics. Phenyl boric acid, its salts, and substituent derivatives (e.g., substituted phenyl) effectively inhibit the growth of several cancer cell lines and offer utility in the treatment/prevention of cancer. The material may be applied or injected into affected areas or applied topically, especially for the treatment of cervical
Market Opportunity
Cervical cancer is the second most common cancer diagnosis in women and is linked to high-risk human papillomavirus infection 99.7% of the time. A significant unmet need exists for early and accurate diagnosis of oncogenic HPV infection as well as for treatments directed at the causative HPV infection, preventing the development of cervical cancer by intervening earlier in disease progression.
Features & Benefits
•The method is a treatment of cancer in tissue, especially tissue of a cervix, comprising the ingestion, injection infusion or application of an ingredient or composition comprising an aromatic boric acid, such as phenyl boric acid or their salts and substituent derivatives so as to treat the affected (e.g., precancerous or cancerous) tissue. The treatment is with an amount of ingredient that inhibits the growth of at least one cancer cell line, which may be in picograms or nanogarms or milligrams per square centimeter for each dosage. Typical topical applications are likely to be within the range of about 0.05-10 ml of 0.5-5% by weight solution, gel, cream, paste or suspension of PBA per square centimeter of surface area of application.
•The anti-aminophospholipid and anti-anionic phospholipid antibodies and therapeutics of the invention may be administered in combination with one or more chemotherapeutic agents or drugs. Chemotherapeutic drugs can kill proliferating tumor cells, enhancing the necrotic areas created by the overall treatment. The drugs can enhance the thrombotic action of the primary therapeutic agents of the invention.
Intellectual Property Patent No.: 8,426,387